Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Vaccine ; 40(20): 2869-2874, 2022 05 03.
Article in English | MEDLINE | ID: covidwho-1768585

ABSTRACT

BACKGROUND: In partial response to the coronavirus disease 2019 (COVID-19) pandemic, countries around the world are conducting large-scale vaccination campaigns. Real-world estimates of vaccine effectiveness (VE) against the B.1.617.2 (Delta) variant are still limited. An outbreak in Ruili city of Chinaprovided an opportunity to evaluate VE against the Delta variant of two types of COVID-19 vaccines in use in China and globally - inactivated (CoronaVac and BBIBP-CorV) and adenovirus type 5 vectored (Convidecia) vaccines. METHODS: We estimated VE using a retrospective cohort study two months after the Ruili vaccination campaign (median: 63 days). Close contacts of infected people (Chinese nationality, 18 years and above) were included to assess VE against symptomatic Covid-19, COVID-19 pneumonia, and severe COVID-19. We calculated the relative risks (RR) of the outcomes for unvaccinated compared with fully vaccinated individuals. We used logistic regression analyses to estimate adjusted VEs, controlling for gender and age group (18-59 years and 60 years and over).We compared unvaccinated and fully vaccinated individuals on duration of RT-PCR positivity and Ct value. FINDINGS: There were 686 close contacts eligible for VE estimates. Adjusted VE ofad5-vectored vaccine was 61.5% (95% CI, 9.5-83.6) against symptomatic COVID-19, 67.9% (95%CI: 1.7-89.9) against pneumonia, and 100% (95%CI: 36.6-100) against severe/critical illness. For the two inactivated vaccines, combined VE was 74.6% (95% CI, 36.0-90.0) against symptomatic COVID-19, 76.7% (95% CI: 19.3-93.3) against pneumonia, and 100% (95% CI: 47.6-100) against severe/critical COVID-19. There were no statistically significant differences in VE between twoinactivated vaccines for symptomatic COVID-19 and for pneumonia, nor were there statistically significant differences between inactivated and ad5-vectored VE in any of the three outcomes. The median durations of RT-PCR positivity were 17 days for fifteen people vaccinated with an inactivated vaccine, 18 days for forty-four people vaccinated with the Ad5 vectored vaccine, and 26 days for eleven unvaccinated individuals. INTERPRETATION: These results provide reassuring evidence that the three vaccines are effective at preventing Delta-variant COVID-19 in short term following vaccination campaign, and are most effective at preventing more serious illness. The findings of reduced duration of RT-PCR positivity and length of hospital stay associated with full vaccination suggests potential saving of health-care system resources.


Subject(s)
COVID-19 Vaccines , COVID-19 , Adenoviridae/genetics , Adolescent , Adult , COVID-19/epidemiology , COVID-19/prevention & control , China/epidemiology , Disease Outbreaks/prevention & control , Humans , Middle Aged , Retrospective Studies , SARS-CoV-2 , Young Adult
2.
Eur J Med Chem ; 234: 114209, 2022 Apr 15.
Article in English | MEDLINE | ID: covidwho-1719653

ABSTRACT

Thirty-two clofazimine derivatives, of which twenty-two were new, were synthesized and evaluated for their antiviral effects against both rabies virus and pseudo-typed SARS-CoV-2, taking clofazimine (1) as the lead. Among them, compound 15f bearing 4-methoxy-2-pyridyl at the N5-position showed superior or comparable antiviral activities to lead 1, with the EC50 values of 1.45 µM and 14.6 µM and the SI values of 223 and 6.1, respectively. Compound 15f inhibited rabies and SARS-CoV-2 by targeting G or S protein to block membrane fusion, as well as binding to L protein or nsp13 to inhibit intracellular biosynthesis respectively, and thus synergistically exerted a broad-spectrum antiviral effect. The results provided useful scientific data for the development of clofazimine derivatives into a new class of broad-spectrum antiviral candidates.


Subject(s)
Antiviral Agents , COVID-19 , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Clofazimine , Humans , SARS-CoV-2
3.
Chinese Journal of Immunology ; 36(23):2919-2921, 2020.
Article in Chinese | CAB Abstracts | ID: covidwho-1082626

ABSTRACT

Objective: In current special situation of COVID-19 epidemic, in order to achieve the aim of "non-stop classes", Animal Immunology course team uses rain classroom for webcasts teaching. Through teachers' elaborate preparations, vivid explanations, interesting and diverse classroom interactions, pre-class previews and post-class homework pushes, etc., teaching process was successfully completed and good teaching results weft achieved. Thus, relying on current network technology and popularity of network, it is feasible for universities to conduct live lectures, both to prevent spread of epidemic and to complete teaching tasks.

SELECTION OF CITATIONS
SEARCH DETAIL